Shumail M. Paulus

Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a <scp>SEER</scp>‐medicare analysis

Sikander Ailawadhi, Ryan D. Frank, Pooja Advani et al. · Cancer Medicine · 2017 · 88 citations · Full text

Medicine, Hematology, Oncology +13

Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells

Aneel Paulus, Sharoon Akhtar, Thomas R. Caulfield et al. · Blood Cancer Journal · 2016 · 62 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities

Sikander Ailawadhi, Ryan D. Frank, Mayank Sharma et al. · Cancer · 2018 · 56 citations · Full text

Medicine, Pharmacoeconomics, Epidemiologic Methods +13

Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment

Aneel Paulus, Sharoon Akhtar, Hamza Yousaf et al. · Blood Cancer Journal · 2017 · 54 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells

Aneel Paulus, Alak Manna, Sharoon Akhtar et al. · British Journal of Haematology · 2018 · 19 citations · Full text

Medicine, Oncology, Pharmacology +17